Across TCGA pan-cancer cohorts, PI4KAP2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated PI4KAP2 data layer compared with 25 for mass-spec protein.
The strongest signal is observed in colon adenocarcinoma (COAD), where higher PI4KAP2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PI4KAP2 expression acts as an unfavorable survival marker.
COAD and STAD are the cancer types where PI4KAP2 Mutation most reproducibly stratifies survival.